Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

ADAR1 Polyclonal Antibody, RBITC Conjugated

Product Specifications

Background

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing) . Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3) . Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1) . Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1) . Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence.

Synonyms

DSH; AGS6; G1P1; IFI4; P136; ADAR1; DRADA; DSRAD; IFI-4; K88DSRBP; Double-stranded RNA-specific adenosine deaminase; 136 kDa double-stranded RNA-binding protein; Interferon-inducible protein 4; ADAR

Gene ID

103

Swiss Prot

P55265

Cellular Locus

Cytoplasm, Nucleus

Host

Rabbit

Cross Reactivity

Human

Immunogen

151-250/1226

Target

ADAR1

Clonality

Polyclonal

Isotype

IgG

Conjugation

RBITC

Source

KLH conjugated synthetic peptide derived from human ADAR1

Applications

WB, IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Excitation Emission

570nm/595nm

Concentration

1µg/µl

Dilution

WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Buffer

Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Modification

Unmodified

Storage Conditions

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Product Datasheet

https://www.biossantibodies.com/datasheets/bs-2167R-RBITC

Gene ID URL

103

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

RSU1 Human
OM302293-01 5 µg

RSU1 Human

Ask
View Details
RSU1 Human
OM302293-02 20 µg

RSU1 Human

Ask
View Details
RSU1 Human
OM302293-03 1 mg

RSU1 Human

Ask
View Details
Vmp1-set siRNA/shRNA/RNAi Lentivector (Rat)
49848096 4 x 500 ng

Vmp1-set siRNA/shRNA/RNAi Lentivector (Rat)

Ask
View Details
Lentiviral mouse Ddx46 shRNA (UAS) - Lentiviral mouse Ddx46 shRNA (UAS, RFP) plasmid
GTR15169537 1 Vial

Lentiviral mouse Ddx46 shRNA (UAS) - Lentiviral mouse Ddx46 shRNA (UAS, RFP) plasmid

Ask
View Details
Thrombopoietin Mouse Recombinant (TPO Mouse)
PT_42247-01 2 µg

Thrombopoietin Mouse Recombinant (TPO Mouse)

Ask
View Details